Business Segments · Net Income
Reportable Segment — Net Income
Eli Lilly Reportable Segment — Net Income increased by 11.4% to $7.40B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 168.1%, from $2.76B to $7.40B. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Net Income shows an upward trend with a 49.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026Apr 30, 2026
Rolls up toNet Income
How to read this metric
Consistent growth in net income signals a healthy, scalable business model with effective cost management.
Detailed definition
Represents the final profitability of the segment after accounting for all revenues, operating expenses, and other segme...
Peer comparison
Comparable to segment operating profit or segment net income in peer financial reporting.
Metric ID:
lly_segment_reportable_segment_net_incomeHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.56B | $1.56B | $1.56B | $1.56B | $1.31B | $1.31B | $1.31B | $1.31B | $2.24B | $2.97B | $970.30M | $4.41B | $2.76B | $5.66B | $5.58B | $6.64B | $7.40B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -16.1% | +0.0% | +0.0% | +0.0% | +71.2% | +32.3% | -67.3% | +354.5% | -37.4% | +105.2% | -1.4% | +18.9% | +11.4% |
| YoY Change | — | — | — | — | -16.1% | -16.1% | -16.1% | -16.1% | +71.2% | +126.5% | -25.9% | +236.6% | +23.0% | +90.8% | +475.3% | +50.5% | +168.1% |
Range$970.30M – $7.40B
CAGR+47.5%
Avg YoY Growth+88.6%
Median YoY Growth+50.5%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — net income?
- Eli Lilly (LLY) reported reportable segment — net income of $7.40B in Q1 2026.
- How has Eli Lilly's reportable segment — net income changed year-over-year?
- Eli Lilly's reportable segment — net income increased by 168.1% year-over-year, from $2.76B to $7.40B.
- What is the long-term trend for Eli Lilly's reportable segment — net income?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — net income has grown at a 49.0% compound annual growth rate (CAGR), from $6.24B to $20.64B.
- What does reportable segment — net income mean?
- The total profit earned by the segment after all associated costs and expenses.